BR112022011073A2 - Estabilização do retromer para o tratamento da doença de alzheimer e outros doenças neurodegenerativas - Google Patents

Estabilização do retromer para o tratamento da doença de alzheimer e outros doenças neurodegenerativas

Info

Publication number
BR112022011073A2
BR112022011073A2 BR112022011073A BR112022011073A BR112022011073A2 BR 112022011073 A2 BR112022011073 A2 BR 112022011073A2 BR 112022011073 A BR112022011073 A BR 112022011073A BR 112022011073 A BR112022011073 A BR 112022011073A BR 112022011073 A2 BR112022011073 A2 BR 112022011073A2
Authority
BR
Brazil
Prior art keywords
disease
alzheimer
treatment
retromer
stabilization
Prior art date
Application number
BR112022011073A
Other languages
English (en)
Portuguese (pt)
Inventor
A Small Scott
Petsko Gregory
H Qureshi Yasir
D Waksal Samuel
Forbes Alexandria
Cox Rebecca
Original Assignee
Univ Columbia
Univ Cornell
Meiragtx Uk Ii Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, Univ Cornell, Meiragtx Uk Ii Ltd filed Critical Univ Columbia
Publication of BR112022011073A2 publication Critical patent/BR112022011073A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022011073A 2019-12-05 2020-12-07 Estabilização do retromer para o tratamento da doença de alzheimer e outros doenças neurodegenerativas BR112022011073A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943999P 2019-12-05 2019-12-05
US202063074578P 2020-09-04 2020-09-04
PCT/US2020/063627 WO2021113824A1 (en) 2019-12-05 2020-12-07 Stabilization of retromer for the treatment of alzheimer's disease and other neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BR112022011073A2 true BR112022011073A2 (pt) 2022-09-20

Family

ID=76222705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011073A BR112022011073A2 (pt) 2019-12-05 2020-12-07 Estabilização do retromer para o tratamento da doença de alzheimer e outros doenças neurodegenerativas

Country Status (12)

Country Link
US (1) US20230021959A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069315A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023505271A (cg-RX-API-DMAC7.html)
KR (1) KR20220152192A (cg-RX-API-DMAC7.html)
CN (2) CN120114618A (cg-RX-API-DMAC7.html)
AU (1) AU2020395327A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011073A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160785A1 (cg-RX-API-DMAC7.html)
IL (1) IL293599A (cg-RX-API-DMAC7.html)
MX (1) MX2022006895A (cg-RX-API-DMAC7.html)
PH (1) PH12022551373A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021113824A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023003655A (es) 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector neurod1.
US20250161243A1 (en) * 2022-02-21 2025-05-22 The Scripps Research Institute Mef2 transcriptional activators to treat neurologic conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20080214482A1 (en) * 2005-11-15 2008-09-04 Scott Small Retromer-based assays and methods for treating alzheimer's disease
WO2009108274A2 (en) * 2008-02-26 2009-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
EP2607900A1 (de) * 2011-12-22 2013-06-26 Protagen AG Markersequenzen für Brustkrebs und deren Verwendung
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
US20160250182A1 (en) * 2013-01-11 2016-09-01 The Trustees Of Columbia University In The City Of Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson's disease risk
WO2014110481A2 (en) * 2013-01-11 2014-07-17 The Trustees Of Columbia University In The City Of New York Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson' s disease risk
GB201409519D0 (en) * 2014-05-29 2014-07-16 Univ Leicester Senescent cell biomarkers
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2018112446A2 (en) * 2016-12-18 2018-06-21 Selonterra, Inc. Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
EP3692158A4 (en) * 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
US20190345516A1 (en) * 2018-03-12 2019-11-14 Musc Foundation For Research Development Methods for treating eye disease

Also Published As

Publication number Publication date
CN120114618A (zh) 2025-06-10
EP4069315A1 (en) 2022-10-12
IL293599A (en) 2022-08-01
EP4069315A4 (en) 2024-03-20
KR20220152192A (ko) 2022-11-15
CN115297891A (zh) 2022-11-04
JP2023505271A (ja) 2023-02-08
CA3160785A1 (en) 2021-06-10
AU2020395327A1 (en) 2022-07-21
JP2025149978A (ja) 2025-10-08
PH12022551373A1 (en) 2023-05-08
WO2021113824A1 (en) 2021-06-10
US20230021959A1 (en) 2023-01-26
MX2022006895A (es) 2022-11-09

Similar Documents

Publication Publication Date Title
WO2021163681A3 (en) Combination of retromer pharmacological chaperones and exogenous retromer for treatment of alzheimer's disease and other neurodegenerative diseases
CY1123734T1 (el) Καταστολη συμπληρωματος για βελτιωμενη αναγεννηση νευρου
BR112022012230A2 (pt) Variantes de progranulina
MX2021014274A (es) Moleculas de union anti-tdp-43 y usos de las mismas.
MX2019007338A (es) Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo.
MX2021005886A (es) Compuestos y metodos para reducir la expresion de priones.
PL4259796T3 (pl) Środki terapeutyczne do leczenia zaburzeń neurodegeneracyjnych
CO2019006785A2 (es) Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades
BR112021021062A2 (pt) Compostos e métodos que alvejam tau humano
BR112017022568A2 (pt) compostos e seus usos como inibidores de bace1
MX2023009652A (es) Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras.
EA201890090A1 (ru) Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения
MX2020012979A (es) Métodos para aumentar la exposición al plasma de sepiapterina.
MX2016007808A (es) Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo.
WO2019075456A3 (en) Methods and substances for prevention and treatment of neurodegenerative diseases
MX2022006895A (es) Estabilizacion de retromero para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
BR112014031531A2 (pt) composto, composição farmacêutica, métodos de tratamento ou prevenção de uma patologia relacionada com ab, e, de tratamento ou prevenção de mal de alzheimer em um paciente em necessidade do mesmo
EA201691602A1 (ru) Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств
EP4048799A4 (en) Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders
BR112018011994A2 (pt) derivados solúveis em água de compostos 3,5-difenil-diazólicos
MX2016000724A (es) Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
WO2009155069A8 (en) Compositions and methods for treating psychiatric and neurodegenerative disorders
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas